Free Trial
NASDAQ:HOOK

Hookipa Pharma Q1 2024 Earnings Report

Hookipa Pharma logo
$1.62 +0.10 (+6.58%)
Closing price 04:00 PM Eastern
Extended Trading
$1.59 -0.03 (-1.85%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Hookipa Pharma EPS Results

Actual EPS
$1.20
Consensus EPS
-$1.20
Beat/Miss
Beat by +$2.40
One Year Ago EPS
-$2.70

Hookipa Pharma Revenue Results

Actual Revenue
$36.60 million
Expected Revenue
$3.20 million
Beat/Miss
Beat by +$33.40 million
YoY Revenue Growth
N/A

Hookipa Pharma Announcement Details

Quarter
Q1 2024
Time
Before Market Opens
Conference Call Date
Thursday, May 9, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Hookipa Pharma's Q1 2025 earnings is scheduled for Wednesday, August 6, 2025

Hookipa Pharma Earnings Headlines

Hookipa Pharma (HOOK) Receives a Hold from RBC Capital
Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
Hookipa Pharma Drops Poolbeg Takeover Bid
See More Hookipa Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hookipa Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hookipa Pharma and other key companies, straight to your email.

About Hookipa Pharma

Hookipa Pharma (NASDAQ:HOOK)., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

View Hookipa Pharma Profile

More Earnings Resources from MarketBeat